 Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 12 Clinical Trial in Q4 2022 Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 12 Clinical Trial in Q4 2022 